Literature DB >> 28374910

A quantitative method for the determination of bosutinib in human plasma using high-performance liquid chromatography and ultraviolet detection.

Takahiro Sumimoto1, Ryosuke Nakahara1, Yuhki Sato1, Hiroki Itoh1.   

Abstract

BACKGROUND: We propose a simple, sensitive, and fast high-performance liquid chromatography ultraviolet detection (HPLC-UV) method for the quantitative determination of bosutinib in human plasma.
METHODS: Plasma samples were processed using an Oasis hydrophilic-lipophilic balance extraction cartridge (1 mL, 30 mg). Bosutinib and the internal standard imatinib were separated using a mobile phase of 0.5% Na2 PO4 H2 O (pH 3.5)-acetonitrile-methanol (55:25:20, v/v/v) on a CAPCELL PAK C18 MG II reversed-phase column 250 nm×4.6 nm i.d., at a flow rate of 1.0 mL/min, with ultraviolet detection at 250 nm.
RESULTS: The calibration curve exhibited linearity over the bosutinib concentration range of 25-1500 ng/mL at 250 nm, with coefficient of variation for intraday precision of 2.42%, 6.04%, and 1.11% for 100, 250, and 1500 ng/mL, respectively, of bosutinib. The lower limit of detection was 20 ng/mL. The extraction recovery rates for bosutinib ranged from 84.36% to 85.82%. The intra- and interday precision was below 8.7%, and the accuracy ranged from -5.95% to 5.85% over the linear range. No notable matrix effects or astaticism were observed.
CONCLUSION: The proposed HPLC-UV method was successfully applied as an assay to detect bosutinib in human plasma.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  assay; bosutinib; chromic myeloid leukemia; high-performance liquid chromatography

Mesh:

Substances:

Year:  2017        PMID: 28374910      PMCID: PMC6816909          DOI: 10.1002/jcla.22201

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  11 in total

1.  Bioanalytical method validation--a revisit with a decade of progress.

Authors:  V P Shah; K K Midha; J W Findlay; H M Hill; J D Hulse; I J McGilveray; G McKay; K J Miller; R N Patnaik; M L Powell; A Tonelli; C T Viswanathan; A Yacobi
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.

Authors:  Miriam Puttini; Addolorata Maria Luce Coluccia; Frank Boschelli; Loredana Cleris; Edoardo Marchesi; Arianna Donella-Deana; Shaheen Ahmed; Sara Redaelli; Rocco Piazza; Vera Magistroni; Federica Andreoni; Leonardo Scapozza; Franca Formelli; Carlo Gambacorti-Passerini
Journal:  Cancer Res       Date:  2006-11-17       Impact factor: 12.701

3.  Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.

Authors:  Stephane Picard; Karine Titier; Gabriel Etienne; Emmanuelle Teilhet; Dominique Ducint; Marie-Agnes Bernard; Regis Lassalle; Gerald Marit; Josy Reiffers; Bernard Begaud; Nicholas Moore; Mathieu Molimard; Francois-Xavier Mahon
Journal:  Blood       Date:  2006-12-27       Impact factor: 22.113

4.  Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection.

Authors:  Masatomo Miura; Naoto Takahashi; Ken-ichi Sawada
Journal:  J Chromatogr Sci       Date:  2011-05       Impact factor: 1.618

5.  A phase 1/2 study of bosutinib in Japanese adults with Philadelphia chromosome-positive chronic myeloid leukemia.

Authors:  Chiaki Nakaseko; Naoto Takahashi; Kenichi Ishizawa; Yukio Kobayashi; Kazuteru Ohashi; Yasunori Nakagawa; Kazuhito Yamamoto; Koichi Miyamura; Masafumi Taniwaki; Masaya Okada; Tatsuya Kawaguchi; Atsushi Shibata; Yosuke Fujii; Chiho Ono; Kazunori Ohnishi
Journal:  Int J Hematol       Date:  2014-12-25       Impact factor: 2.490

6.  SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.

Authors:  Jennifer M Golas; Kim Arndt; Carlo Etienne; Judy Lucas; Danielle Nardin; James Gibbons; Philip Frost; Fei Ye; Diane H Boschelli; Frank Boschelli
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

7.  Population pharmacokinetic and pharmacodynamic analysis of bosutinib.

Authors:  Poe-Hirr Hsyu; Diane R Mould; Richat Abbas; Michael Amantea
Journal:  Drug Metab Pharmacokinet       Date:  2014-06-10       Impact factor: 3.614

8.  A simple method for the determination of Bosutinib in rat plasma by UPLC-MS/MS.

Authors:  Yihua Xu; Xin-ce Huang; Shengjie Dai; Yuwu Xiao; Meng-tao Zhou
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-09-25       Impact factor: 3.205

9.  Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.

Authors:  Richard A Larson; Brian J Druker; Francois Guilhot; Stephen G O'Brien; Gilles J Riviere; Tillmann Krahnke; Insa Gathmann; Yanfeng Wang
Journal:  Blood       Date:  2008-02-06       Impact factor: 22.113

10.  Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Authors:  H Jean Khoury; Jorge E Cortes; Hagop M Kantarjian; Carlo Gambacorti-Passerini; Michele Baccarani; Dong-Wook Kim; Andrey Zaritskey; Athena Countouriotis; Nadine Besson; Eric Leip; Virginia Kelly; Tim H Brümmendorf
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113

View more
  1 in total

1.  Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high-performance liquid chromatography-Photodiode array detection.

Authors:  Yuta Yokoyama; Eiji Nozawa; Miho Morita; Emi Ishikawa; Takehiko Mori; Masatoshi Sakurai; Taku Kikuchi; Eri Matsuki; Rie Yamazaki; Keisuke Kataoka; Aya Jibiki; Hitoshi Kawazoe; Sayo Suzuki; Tomonori Nakamura
Journal:  J Clin Lab Anal       Date:  2022-07-12       Impact factor: 3.124

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.